Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 785 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gene Expression Clear all

Conditions: Non Small Cell Lung Cancer
Interventions: Pegilodecakin, Nivolumab; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 35
States / cities: Tempe, Arizona • Beverly Hills, California • Los Angeles, California + 30 more

Conditions: HIV-1 Seropositive, Inflammation, Cancer, Cardiomyopathy
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 178 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Sepsis, Systemic Inflammatory Response Syndrome (SIRS)
Interventions: Not listed
Lead sponsor: Immunexpress; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 379 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Atlanta, Georgia • Chicago, Illinois • Maywood, Illinois + 3 more

Conditions: Gastrointestinal Disorders
Interventions: Gluten Healthy, Placebo; Dietary Supplement · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions: REGN5678, Cemiplimab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 24
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 17 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Muscular Dystrophy, Duchenne
Interventions: PF-06939926; Genetic
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 3 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: Gainesville, Florida • Philadelphia, Pennsylvania • Salt Lake City, Utah

Conditions: Inflammation
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Esophageal Neoplasm, Head and Neck Neoplasm, Laryngeal Neoplasm, Papilloma, Squamous Cell Carcinoma
Interventions: Not listed
Lead sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD); NIH
Eligibility: Not listed
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Solid Tumor, Unspecified, Adult
Interventions: Determination of ATM alteration status.; Other
Lead sponsor: Artios Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Nashville, Tennessee

Conditions: Rhinosinusitis
Interventions: Observational study; Other
Lead sponsor: Monell Chemical Senses Center; Other
Eligibility: 21 Years to 50 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Breast Cancer patient, Cancer patients; Procedure
Lead sponsor: Applied Spectral Imaging Ltd.; Industry
Eligibility: 20 Years to 80 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Breast Cancer
Interventions: anastrozole, Placebo; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 45 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis, Eczema
Interventions: Crisaborole; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 4 Months to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cardiac Transplant Failure, Cardiac Transplant Rejection, Heart Diseases
Interventions: Not listed
Lead sponsor: CareDx; Industry
Eligibility: 15 Years and older
Enrollment: 2,444 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 36
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 27 more

Conditions: Borderline Personality Disorder
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Survivors of Pediatric Brain Tumors, Pediatric Cancer
Interventions: FaceSay, SuccessMaker Reading; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 6 Years to 13 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Urothelial Carcinoma
Interventions: Pembrolizumab, Lenvatinib, Placebo for lenvatinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 21
States / cities: Gilbert, Arizona • Clovis, California • Orange, California + 18 more

Conditions: Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer
Interventions: Azacitidine, Entinostat, Laboratory Biomarker Analysis, Pharmacological Study, Therapeutic Conventional Surgery; Drug · Other · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Lexington, Kentucky • Albuquerque, New Mexico • Dallas, Texas

Conditions: Endocrine Tumors, Thyroid Neoplasms, Parathyroid Neoplasms, Adrenal Neoplasm, Neuroblastoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 4 Years and older
Enrollment: 2,415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Rosacea
Interventions: Skin Biopsy; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Amyotrophic Lateral Sclerosis
Interventions: GM604, Placebo comparator; Drug
Lead sponsor: Genervon Biopharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Urothelial Carcinoma
Interventions: Not listed
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 11
States / cities: Phoenix, Arizona • Orange, California • Palo Alto, California + 8 more

Conditions: Controlled Ovarian Stimulation
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 31 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2014
U.S. locations: 1
States / cities: Lutherville, Maryland

Search by objective public record fields.

Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Study of the Effect of SNPs in p53 and p53 Response Elements on the Inflammatory Response to DNA Damage

VENUS: Septic Gene Expression Using SeptiCyte

Change in Permeability of the Small Intestine After Treatment With Gluten

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

A Pilot Study of the Patterns of Cellular Gene Expression in HIV-1 Patients Following Clinical Events Which Increase Plasma Virus Concentrations

Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy

Effect of Glucose Load on Expression of Advanced Glycation End Products in Women Screened for Gestational Diabetes

The Effects of Upper Airway and Digestive Tract Tumors on the Immune System

Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein

Allele-specific Expression of a Bitter Taste Receptor

Identification and Semi -Quantification of ER/PR Proteins Expression

Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer

Response of Children With Atopic Dermatitis (Eczema) to Eucrisa

Outcomes AlloMap Registry: the Long-term Management and Outcomes of Heart Transplant Recipients With AlloMap Testing

MRI Imaging in Borderline Personality Disorder

Facial Expression Awareness Training to Understand and Recognize Emotions

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

Genetic Basis of Rosacea Study (Control)

GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)

HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

Endometrial Luteal Phase Characteristics and Luteal Phase Support in Controlled Ovarian Stimulation Protocols With GnRH Antagonists:Focusing on MicroRNA